INVO Bioscience Announces the Closing to the Bridge Financing

BEVERLY, Mass.--(Business Wire)--
INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on
treatment options for patients diagnosed with infertility, announced that the
$500,000 private placement / or equity securities financing that was outlined in
the 8K filing dated July of 2009 has been fully subscribed. "This financing will
allow INVO to bridge to long term financing in which terms are currently being
negotiated as well as allow us to continue to with product launch," said INVO
Bioscience`s CEO, Kathleen Karloff.

About the INVO Procedure

The INVOcell and INVO Procedure combine a natural or mild (mild medication)
stimulation infertility treatment cycle, using lower amounts of fertility
hormones than used in traditional IVF (in vitro fertilization), with
intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg
retrieval, the woman`s eggs (oocytes) are combined with sperm in the INVOcell, a
small device, which is then sealed and placed in the woman`s vaginal cavity to
incubate for three days. When the INVOcell is removed, the anticipated one to
two developing embryos are transferred directly into the woman's uterine cavity,
where implantation and continued pregnancy can take place.

The company has received European CE Mark approval for the INVOcell and, in
2008, launched the product in select countries outside the U.S. The company is
also pursuing U.S. Food and Drug Administration 510(k) clearance for the
INVOcell.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly,
Massachusetts, focused on creating simplified, lower cost treatment options for
patients diagnosed with infertility. The company`s lead product, the INVOcell,
is a novel medical device used in infertility treatment that enables egg
fertilization and early embryo development in the woman`s vaginal cavity. The
company was founded by Claude Ranoux, MD, a noted expert in the field of
reproductive health, infertility and embryology. For more information, please
visit www.invo-bioscience.com.

This release includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. All statements regarding our expected future
financial position, results of operations, cash flows, financing plans, business
strategies, products and services, competitive positions, growth opportunities,
plans and objectives of management for future operations, as well as statements
that include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. All forward-looking statements
involve risks, uncertainties and contingencies, many of which are beyond our
control, which may cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements. Factors that
may cause actual results to differ materially from those in the forward-looking
statements include those set forth in our filings at www.sec.gov. We are under
no obligation to (and expressly disclaim any such obligation to) update or alter
our forward-looking statements, whether as a result of new information, future
events or otherwise.

INVO Bioscience, Inc.
Kathleen Karloff, 978-878-9505
www.invobioscience.com

Copyright Business Wire 2009